ArticleFrontiers in oncology2026
Construction of a prediction model for axillary lymph node metastasis in stage cN0 hormone receptor-positive breast cancer: based on interpretable machine learning methods.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Accurately predicting axillary lymph node metastasis (ALNM) preoperatively is crucial for optimizing management in patients with clinically node-negative (cN0) hormone receptor-positive (HR+) breast cancer (BC). Methods: We retrospectively analyzed 816 cN0 HR+ BC patients (2016-2024). Data from 2016-2023 (n=726) were randomly assigned to a training set (n=503) or an internal test set (n=223) in a 7:3 ratio. Patients treated in the most recent year, 2024 (n=90), were reserved as a held-out temporal validation set. Following feature selection via Recursive Feature Elimination (RFE), five machine learning models-XGBoost, Random Forest, Logistic Regression, Support Vector Machine, and K-Nearest Neighbors (KNN)-were developed. Performance was assessed by the area under the receiver operating characteristic curve (AUC) and decision curve analysis (DCA). The optimal model was interpreted using SHapley Additive exPlanations (SHAP). Results: The incidence of ALNM was 30.9%. The KNN model demonstrated optimal performance, achieving an AUC of 0.898 (95% CI: 0.857-0.939) in the test set and 0.774 (95% CI: 0.655-0.892) in the external validation set. DCA indicated that the KNN model provided the highest net clinical benefit within the 30%-65% threshold probability range. SHAP analysis identified parity as the most critical predictor, followed by age, tumor location, menopausal status, tumor diameter, lymphocyte count, platelet count, alpha-fetoprotein (AFP), neutrophil count, and carcinoembryonic antigen (CEA). Conclusion: The KNN model, integrated with the SHAP interpretability framework, shows favorable performance, interpretability, and clinical applicability for predicting ALNM in cN0 HR+ BC, offering a valuable tool for preoperative risk assessment and individualized decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.